Ernie. re ICU
Biggest market will be the adult population ...and that may be several yrs away even if this interim analysis is really positive .
JMO
Good luck
Kiwi
DENVER, May 13, 2025 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and potential loss of life, announced today that it has successfully reached the halfway point in the NEUTRALIZE-AKI pivotal clinical trial, enabling a per protocol prespecified interim analysis by the trial’s independent Data Safety Monitoring Review Board (DSMB)
. SeaStar Medical anticipates the DSMB will report its findings to the company in the third quarter of 2025
Biggest market will be the adult population ...and that may be several yrs away even if this interim analysis is really positive .
JMO
Good luck
Kiwi
Recent AMLX News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/26/2026 08:00:07 PM
- Amylyx Pharmaceuticals Announces Peer-Reviewed Publication of Phase 2 Open-Label HELIOS Trial Data for AMX0035 in The Journal of Clinical Investigation • Business Wire • 05/15/2026 04:11:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/07/2026 11:04:48 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/07/2026 11:02:56 AM
- Amylyx Pharmaceuticals Reports First Quarter 2026 Financial Results • Business Wire • 05/07/2026 11:00:00 AM
- Amylyx Pharmaceuticals to Participate in Upcoming Investor Conferences • Business Wire • 05/06/2026 01:00:00 PM
- Amylyx Pharmaceuticals Announces U.S. Expanded Access Program for Adults with Post-Bariatric Hypoglycemia • Business Wire • 05/05/2026 11:00:00 AM
- Amylyx Pharmaceuticals to Report First Quarter 2026 Financial Results on May 7, 2026 • Business Wire • 04/30/2026 01:00:00 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 04/23/2026 11:03:13 AM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 04/23/2026 11:02:00 AM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/23/2026 11:01:02 AM
- Amylyx Pharmaceuticals to Present at the 25th Annual Needham Virtual Healthcare Conference • Business Wire • 04/08/2026 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/24/2026 11:11:11 AM
- Amylyx Pharmaceuticals Announces Completion of Enrollment in Pivotal Phase 3 LUCIDITY Clinical Trial of Avexitide in Post-Bariatric Hypoglycemia • Business Wire • 03/24/2026 11:00:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/09/2026 08:00:08 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/09/2026 08:00:05 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/04/2026 09:00:13 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/04/2026 09:00:02 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 03/03/2026 09:03:34 PM
- Amylyx Shares Slip Despite Q4 Beat as Investors Focus on Trial Timeline • IH Market News • 03/03/2026 03:54:22 PM
- Form S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuers • Edgar (US Regulatory) • 03/03/2026 01:01:18 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/03/2026 12:10:58 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/03/2026 12:02:50 PM
- Amylyx Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results • Business Wire • 03/03/2026 12:00:00 PM
